JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Odonate Therapeutics Inc

Open

0

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Schlüsselkennzahlen

By Trading Economics

Odonate Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Okt. 2025, 23:50 UTC

Heiße Aktien

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28. Okt. 2025, 23:25 UTC

Ergebnisse

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28. Okt. 2025, 23:18 UTC

Ergebnisse

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28. Okt. 2025, 22:20 UTC

Ergebnisse

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28. Okt. 2025, 22:13 UTC

Ergebnisse

Wal-Mart de Mexico Net Profit Falls in 3Q

28. Okt. 2025, 21:38 UTC

Ergebnisse

Correction to Visa Sales Jump Article

28. Okt. 2025, 21:17 UTC

Ergebnisse

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28. Okt. 2025, 21:07 UTC

Ergebnisse

Visa Sales Jump as Consumers Keep Spending -- Update

28. Okt. 2025, 21:02 UTC

Ergebnisse

Mondelez Tempers Outlook as Costs Rise

28. Okt. 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28. Okt. 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28. Okt. 2025, 23:02 UTC

Ergebnisse

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28. Okt. 2025, 23:01 UTC

Ergebnisse

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28. Okt. 2025, 22:46 UTC

Ergebnisse

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28. Okt. 2025, 22:45 UTC

Ergebnisse

SK Hynix 3Q Net KRW12.6T >000660.SE

28. Okt. 2025, 22:44 UTC

Ergebnisse

SK Hynix 3Q Rev KRW24.44T >000660.SE

28. Okt. 2025, 22:43 UTC

Ergebnisse

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28. Okt. 2025, 22:42 UTC

Ergebnisse

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28. Okt. 2025, 22:40 UTC

Ergebnisse

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28. Okt. 2025, 22:40 UTC

Ergebnisse

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28. Okt. 2025, 22:22 UTC

Ergebnisse

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28. Okt. 2025, 22:20 UTC

Ergebnisse

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28. Okt. 2025, 22:02 UTC

Ergebnisse

Review & Preview: Earnings Extravaganza -- Barrons.com

28. Okt. 2025, 21:42 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

28. Okt. 2025, 21:42 UTC

Market Talk
Ergebnisse

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28. Okt. 2025, 21:20 UTC

Ergebnisse

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28. Okt. 2025, 21:19 UTC

Ergebnisse

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28. Okt. 2025, 21:18 UTC

Ergebnisse

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer-Vergleich

Kursveränderung

Odonate Therapeutics Inc Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat